Suboxone Tooth Decay Lawsuit: Indivior Knew and Said Nothing

Indivior Inc., the maker of Suboxone sublingual film, faces thousands of lawsuits alleging it knew for over a decade that its buprenorphine dissolving strips could destroy patients’ teeth — and chose profits over disclosure. Before the FDA finally forced a warning label update in June 2022, Indivior had already received at least 136 reports of adverse dental events. It sent no alert to prescribing doctors. It updated no patient medication guide. Patients who trusted the drug to help them overcome opioid addiction were left to lose their teeth without warning.

The federal cases are consolidated in MDL 3092, formally titled In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese. As of May 2026, approximately 1,832 lawsuits remain pending in the MDL. Bellwether trials — early test cases that guide settlement negotiations for the full litigation — are scheduled to begin in March 2028. New cases are still being accepted, but the statute of limitations in many states is closing the window.

Suboxone Tooth Decay Lawsuit Timeline and Updates

2002 — Suboxone Approved by the FDA

The FDA approved buprenorphine and naloxone under the brand name Suboxone in 2002 as a medication-assisted treatment for opioid use disorder. Originally available in tablet form, the drug helped thousands of Americans manage withdrawal symptoms and reduce opioid cravings. Suboxone became a cornerstone of the national response to the opioid epidemic, prescribed to millions of patients across the country.

2010 — Suboxone Film Introduced; Tablets Discontinued

Indivior reformulated Suboxone from a tablet into a sublingual film — a thin strip that dissolves under the tongue or against the cheek. Plaintiffs and their attorneys argue this reformulation was not purely motivated by clinical improvement. Indivior faced expiring patent protections on the tablet version and the imminent entry of generic competitors. By shifting to the film formulation and filing new patents, the company extended its market exclusivity and blocked cheaper generics for additional years.

The sublingual film design introduced a new variable: prolonged acidic contact with oral tissue and tooth enamel. Each time a patient dissolved a strip in their mouth, the acidic pH of the film was in direct contact with teeth for an extended period. Indivior allegedly possessed data indicating this acidic mechanism could erode enamel and cause dental damage, but did not disclose it to prescribing physicians or patients.

Before 2022 — Adverse Event Reports Accumulate, Warnings Never Issued

Internal records and FDA adverse event databases show that reports of dental injury associated with Suboxone film began accumulating years before any warning was issued. By the time the FDA acted in 2022, Indivior had received at least 136 reports of adverse dental events linked to its buprenorphine products. Among all buprenorphine medications dissolved in the mouth, the FDA identified at least 305 dental adverse event cases total. Of those, 131 were classified as severe.

Despite this growing body of adverse event data, Indivior issued no “Dear Doctor” letter to prescribing physicians — a standard pharmaceutical communication used to alert clinicians to emerging safety signals. It made no updates to the patient medication guide. Patients who took Suboxone as directed, often for years, had no way to connect their worsening dental health to their medication.

January 12, 2022 — FDA Issues Safety Communication

The FDA issued a formal Drug Safety Communication on January 12, 2022, publicly warning that dental problems — including tooth decay, cavities, oral infections, and tooth loss — had been reported in patients using buprenorphine medicines dissolved in the mouth. The communication noted that many of the affected patients had no prior history of dental problems and maintained normal dental hygiene throughout their Suboxone treatment. The FDA directed manufacturers to add dental risk warnings to prescribing information and patient medication guides.

June 2022 — Indivior Updates Suboxone Warning Label

Indivior updated the Suboxone film warning label in June 2022 to reflect the FDA’s safety communication, adding dental risk information for the first time. The update came more than a decade after the film formulation entered the market. Plaintiffs argue the update came too late and remained inadequate, characterizing it as language buried in labeling rather than the direct, prominent physician alert the seriousness of the risk warranted.

A research letter published in the Journal of the American Medical Association following the label update confirmed what plaintiffs had long alleged: sublingual buprenorphine users experienced significantly higher rates of dental injuries compared to patients using alternative forms of buprenorphine, including transdermal patches and injectable formulations. The comparison directly implicated the sublingual film delivery method rather than buprenorphine itself as the mechanism of harm.

2023 — Federal Lawsuits Filed Nationwide; JPML Considers Consolidation

Individual Suboxone tooth decay lawsuits began accumulating in federal courts across the country in 2023. Each complaint named Indivior and related entities as defendants, alleging failure to warn, negligent design, and insufficient pre-market testing. Plaintiffs’ lawyers filed petitions urging the U.S. Judicial Panel on Multidistrict Litigation to consolidate the cases into a single MDL for coordinated pretrial management.

February 2024 — JPML Establishes MDL 3092 in Northern District of Ohio

The U.S. Judicial Panel on Multidistrict Litigation formally created MDL 3092 in February 2024, centralizing all federal Suboxone tooth decay lawsuits before U.S. District Judge J. Philip Calabrese in the Northern District of Ohio. The JPML considered the motion at its January 2024 hearing before issuing the consolidation order. Judge Calabrese began issuing case management orders and initiating the pretrial discovery process.

Mid-2024 — Discovery Begins; Case Count Grows Rapidly

The court issued discovery protocols in mid-2024 and began collecting medical and dental records from plaintiffs. A major procedural development in June 2024 came when Judge Calabrese denied Indivior’s request for phased discovery, ruling that the case would move forward without the limitations Indivior sought. That ruling was a victory for plaintiffs. In July 2024, the court ordered Indivior to produce evidence from its prior antitrust and patent litigation, which attorneys for plaintiffs argued would help demonstrate the company’s awareness of the competitive motivations behind the film reformulation.

A consolidated complaint filed in 2024 bundled over 9,500 plaintiffs from states with short statutes of limitations into a single “Schedule A” filing to preserve their claims before deadlines expired. By August 2024, Indivior sought a partial dismissal of certain claims. The court denied that motion in full.

January 2025 — Court Partially Denies Indivior’s Motion to Dismiss

In a key ruling for plaintiffs, Judge Calabrese partially denied Indivior’s motion to dismiss in January 2025, allowing failure-to-warn claims and pre-approval design defect claims to proceed. The court upheld the argument that Indivior had a duty to explore safer alternatives before receiving FDA approval — citing Sublocade, an injectable buprenorphine formulation that does not require sublingual dissolution and does not carry the same dental risk profile. The ruling narrowed some post-approval design defect claims and focused the failure-to-warn theory on Indivior as the label holder, but the core legal theories survived intact.

April 2025 — Court Issues CMO No. 14; 500-Case Records Pool Established

Judge Calabrese issued Case Management Order No. 14 in April 2025, permitting block filings and initiating a focused review of 500 selected cases for intensive records collection. The court was working to gather prescription histories and dental records from pharmacies and healthcare providers, facing persistent noncompliance from third-party record holders.

September 2025 — Delays From Record Collection; 11,000+ Claims Nationwide

By September 2025, lawyers in more than 11,000 Suboxone dental lawsuits were meeting with Judge Calabrese to address ongoing delays caused by difficulties collecting prescription and dental records from pharmacies and healthcare providers. The court remained focused on the 500 Schedule A cases in a records collection pool. Persistent noncompliance from pharmacies — including CVS, which the court scheduled for a show-cause hearing — continued to slow discovery.

October 2025 — New Case Management Order; Census Forms Required

The MDL judge issued a new case management order in October 2025 requiring plaintiffs to submit census forms within 60 days of filing for all lawsuits brought after October 1, 2025. Plaintiffs who filed between October 2024 and September 2025 must submit census forms by June 1, 2026. The order was designed to manage the volume of incoming claims and ensure each plaintiff’s case had sufficient documentation to proceed.

February 2026 — 100 Representative Cases Selected for Deep Discovery

The court identified 100 representative lawsuits from the broader records collection pool to proceed through coordinated fact discovery in February 2026. These cases form the foundational discovery group from which bellwether trial candidates will ultimately be selected. The court’s systematic approach to narrowing claims toward trial mirrors the standard MDL bellwether selection process used in other major pharmaceutical mass torts.

April 3, 2026 — Bellwether Trial Roadmap Set; First Trial March 2028

Judge Calabrese issued a detailed procedural schedule on April 3, 2026, establishing the complete roadmap toward bellwether trials. Under the order, the court will build a 50-case Core Discovery Pool from the existing 100-case group, beginning with 20 random selections on June 10, 2026, followed by 15 picks from each side on June 24. The final Core Discovery list is due to the court by July 2, 2026.

Core discovery depositions will run from July 13, 2026 through January 15, 2027. The court will then narrow to a 15-case Trial Pool on January 29, 2027, complete case-specific fact discovery by June 4, 2027, and select the four final bellwether trial cases on June 11, 2027. The first bellwether trial is projected to begin in March 2028.

May 4, 2026 — Judge Orders Schedule A Cases Refiled Individually

In a significant procedural ruling on May 4, 2026, the federal judge overseeing MDL 3092 ruled that the thousands of “Schedule A” claims filed together in the 2024 bundled complaints must be refiled as individual lawsuits or dismissed. The decision marked a major procedural shift requiring plaintiffs to formally pursue their cases on their own if they want to continue seeking damages. The original Schedule A bundle contained approximately 9,500 plaintiffs; following dismissals for noncompliance and failure to refile, 5,763 Schedule A claims remained active as of May 2026.

What the Suboxone Lawsuits Allege

Three distinct legal theories power the Suboxone litigation. Each targets a different dimension of Indivior’s alleged failure.

The failure-to-warn claim is the strongest and most broadly surviving theory. Plaintiffs argue that Indivior knew or should have known that dissolving an acidic film strip against tooth enamel repeatedly over months or years would cause dental damage. The company had 136 adverse event reports before the FDA forced action in 2022. It had clinical knowledge of the film’s acidic pH. It never warned doctors. It never warned patients. The failure-to-warn claim survived Indivior’s motion to dismiss in January 2025 and remains the legal center of gravity for the litigation.

The design defect claim argues the sublingual film formulation was inherently dangerous. Plaintiffs point to alternative delivery mechanisms — most directly, Sublocade, an injectable form of buprenorphine that bypasses oral contact entirely. The existence of a safer alternative undermines the argument that the film design was the only feasible option. The court upheld pre-approval design defect claims while narrowing post-approval theories, meaning plaintiffs can argue Indivior should have designed the product differently before it reached the market.

Insufficient pre-market testing is the third pillar. Indivior allegedly did not conduct comprehensive long-term dental safety studies before commercializing the film formulation. Given the known chemistry of placing an acidic substance in repeated contact with tooth enamel, plaintiffs argue the absence of dental-specific safety data before launch was a failure of the basic due diligence pharmaceutical companies owe to patients.

Who Is Being Sued

The defendants named across Suboxone tooth decay complaints include Indivior PLC, Indivior Inc., Indivior Solutions Inc., Reckitt Benckiser LLC, Reckitt Benckiser Healthcare (UK) Ltd., Aquestive Therapeutics Inc., Monosol Rx Inc., and Monosol LLC. Indivior was spun off from Reckitt Benckiser in 2014 and is headquartered in North Chesterfield, Virginia. Aquestive Therapeutics manufactures the Suboxone film for Indivior. The corporate structure covering development, manufacturing, and commercialization of the film creates potential liability across multiple entities.

Indivior’s prior legal history is relevant context. In July 2020, Indivior agreed to pay $600 million to resolve separate Department of Justice criminal and civil charges related to illegal marketing practices and efforts to delay generic Suboxone competition. That settlement did not involve dental injuries. The current MDL 3092 dental litigation is entirely separate and was brought by patients rather than by the government.

Injuries Covered by the Lawsuit

The Suboxone tooth decay lawsuits cover a range of serious dental injuries, all linked to the acidic sublingual film dissolving repeatedly against oral tissue and tooth enamel. Qualifying injuries include severe tooth decay and enamel erosion, tooth fractures and breakage, tooth loss and extractions, oral infections, cavities that developed without prior dental problems, root canals, the need for dental crowns, and patients who required dental implants as a result of tooth loss.

A key fact courts have focused on is that many affected patients had no prior history of dental problems and maintained normal hygiene throughout their Suboxone treatment. The sudden and severe deterioration of dental health in patients with previously healthy teeth creates a stronger causal link between drug use and injury than would exist in patients with pre-existing conditions.

How Can You Still Apply for the Suboxone Lawsuit?

New cases are still being accepted in MDL 3092. Here is how the process works and what determines whether you can still file.

The most important factor is the statute of limitations. Different states apply different time limits, typically two to three years from the date you discovered or should have discovered that Suboxone caused your dental injuries. Because the FDA’s public safety communication was issued in January 2022 and the label update came in June 2022, courts in many states treat 2022 as the discovery date for patients who were not aware of the link before that. That means a two-year deadline in those states would have passed in 2024, and a three-year deadline runs through 2025. However, application of discovery rules varies by state, and some plaintiffs may be able to argue a later discovery date if they did not connect their dental damage to Suboxone until after 2022.

The steps to file are straightforward. First, contact a mass tort attorney who handles pharmaceutical product liability cases. Most Suboxone lawyers work on contingency, meaning you pay nothing unless compensation is recovered. Second, gather your records: prescription history showing you used Suboxone sublingual film, dental records documenting the injuries, and any medical documentation of the harm and treatment. Third, your attorney evaluates whether your state’s statute of limitations still permits filing and whether your injuries meet the eligibility threshold.

To qualify, you generally must have used Suboxone sublingual film specifically — not the tablet formulation — and suffered serious dental injuries as a result. Mild sensitivity or minor issues may not reach the threshold. Severe tooth decay, extractions, tooth loss, infections, root canals, and the need for dental implants are the types of injuries courts and attorneys are focusing on in this litigation.

Cases filed in 2026 can still be included in any global settlement that may result from the bellwether trial process, as long as they are filed before the statute of limitations expires. The window is not permanently closed, but it is narrowing. The longer a former Suboxone user waits, the harder it becomes to gather evidence, locate pharmacy records, and meet procedural deadlines imposed by the court.

Settlement Estimates and What to Expect

No global settlement has been announced in the Suboxone dental injury MDL as of May 2026. Settlement discussions typically begin in earnest after bellwether trials provide both sides with a clearer picture of how juries respond to the evidence and what compensation levels are likely. With the first bellwether trial not expected until March 2028, a global settlement is most likely in the 2027 to 2029 timeframe.

Projected individual payout estimates from legal analysts range from approximately $50,000 to $200,000 or more, depending on the severity of dental injuries, the volume of documented treatment, the duration of Suboxone use, and the strength of individual causation evidence. These are projections only, based on comparisons to other pharmaceutical MDL settlements and the strength of the scientific evidence linking the film formulation to dental harm. No court has certified these numbers.

Factors that influence individual case value include the extent of dental injury documented in records, whether teeth were permanently lost, the cost of dental treatment required, documented pain and suffering, and the duration and dosage of Suboxone film use.

Patients navigating pharmaceutical injury litigation may also want to follow the OGX shampoo lawsuit, where ingredient-linked injury claims raised similar questions about what manufacturers know and when they are required to disclose it. The Costco rotisserie chicken lawsuit examined comparable failure-to-disclose patterns in consumer product safety. The Affirm lawsuit and the Capital One savings case each produced landmark rulings on what companies owe consumers in terms of transparent, timely disclosure of risks — the same standard Suboxone plaintiffs are demanding of Indivior in court.

What This Lawsuit Teaches Consumers

The Suboxone litigation carries a message that goes beyond one drug and one company. Patients who use medication-assisted treatment for opioid addiction are among the most vulnerable populations in the healthcare system. They are fighting addiction. They are often economically stressed. They depend on their doctors and the pharmaceutical companies behind their prescriptions to tell them the truth about what they are putting in their bodies.

Indivior allegedly knew that dissolving an acidic strip against teeth could damage enamel. The company had adverse event reports. It had the science. It made the business calculation that adding a dental warning would undermine the drug’s commercial position and invite liability. So it said nothing — for over a decade — while patients lost their teeth.

The FDA’s 2022 safety communication changed the public record but did not undo the harm already done. It also did not answer the deeper question: how does a pharmaceutical company receive 136 adverse event reports about a known mechanism of harm and conclude that no warning is needed? That is the question the bellwether trials will put before juries starting in March 2028.

For current and former Suboxone users: if you took the sublingual film and your dental health deteriorated significantly during or after your treatment, do not assume the damage was coincidental. Connect with a mass tort attorney, gather your records, and find out whether you are still within the filing window in your state. The litigation is open. The window may not be.